Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

UCB’s Bimzelx sustains joint responses through 24 weeks in psoriatic arthritis trial

By Public Technologies
  • UCB reported BE BOLD trial results showing Bimzelx maintained numerically greater joint improvements than Skyrizi through 24 weeks in psoriatic arthritis.
  • Earlier results, presented at EULAR 2026, demonstrated statistically significant superiority for Bimzelx in joint responses at 16 weeks.
  • Full 24-week results will be presented November 10 at the 2026 ACR Convergence in Orlando, Florida.
  • Secondary outcomes remained numerically better without statistical significance; complete skin clearance was comparable between treatments at 24 weeks.
  • Overall safety was comparable, except for more mild-to-moderate localized Candida infections with Bimzelx; no new safety signals emerged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.